Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025Business Wire • 01/12/25
FDA Updates EXEL on Previously Scheduled ODAC Meeting for CabozantinibZacks Investment Research • 01/10/25
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, ZanzaSeeking Alpha • 01/09/25
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 01/09/25
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025Business Wire • 01/06/25
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?Zacks Investment Research • 01/06/25
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 11/28/24
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in DecemberBusiness Wire • 11/27/24
ODAC to Discuss Exelixis' Application for Cabometyx Label ExpansionZacks Investment Research • 11/27/24
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 11/26/24
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in NovemberBusiness Wire • 11/07/24